The aim of this prospective, uncontrolled clinical study was to evaluate the tolerability and the efficacy of levetiracetam as add-on treatment in 78 adults and 44 children with intractable epilepsy. The patients' seizure frequency in the 8 weeks baseline period was compared to their seizure frequency after a mean follow-up of 8 months of treatment.
INTRODUCTION
Levetiracetam is a new antiepileptic drug (AED) with a unique preclinical profile, favourable pharmacokinetic properties, a wide therapeutic index and a high margin of safety. The drug may also have an antiepileptogenic effect, as it seems to prevent the development of amygdala kindling in rodents 1 . Levetiracetam seems to have a selective stereo-specific binding site in the brain, but its exact mode of action is still unknown 2 .
In clinical studies levetiracetam, given in doses of 500, 1000 and 1500 mg, b.i.d., has proven effective as add-on treatment in adult patients with intractable partial onset seizures with and without secondary generalisation 3 . Lately, the drug has also been shown to have effect on generalised seizures 4 .
We report the results of an uncontrolled, prospective clinical study performed at our tertial referral center. The aim of the study was to evaluate the tolerability and the efficacy of levetiracetam as add-on treatment in both adults and children with difficult-to-treat epilepsy.
PATIENTS AND METHODS
Since September 2000, 78 adults and 44 children with refractory epilepsy have received levetiracetam as add-on treatment at our center. The patient characteristics are shown in Table 1 (adults) and Table 2 (children). Total 13 (17%) of the adults and 39 (89%) of the children were mentally retarded. To be included in the study the patients had to fulfil the following criteria: a verified diagnosis of generalised or localisation-related epilepsy, at least four seizures in the 8-week baseline period, and taking at least one AED. Patients with a progressive neurological disorder or nonepileptic seizures were excluded.
After the 8-week baseline period the patients started treatment with levetiracetam. The dose escalation for The co-medication most frequently used was carbamazepine (CBZ) and valproate (VPA) in the adults, and lamotrigine (LTG) and VPA in the children (Tables 1 and 2 ). The co-medication was kept constant throughout the study in both adults and children.
The adult patients were monitored at our outpatient clinic with 4-6 weeks intervals. At each visit a drug fasting blood sample was drawn for drug analysis of the co-medication, and the seizures (seizure types, frequency, duration, and severity) and side effects were evaluated. The children were monitored by telephone interviews every fortnight, and in special occasions by consultation at the outpatient clinic.
After a mean follow-up period of 8 months the patients' seizure frequency was compared to their baseline condition. Each patient acted as his/her own control.
RESULTS

Adults
After a mean follow-up period of 8 months (3-17 months) 31 patients (40%) were responders, i.e. they achieved >50% reduction in seizure frequency. Seven of these patients (9%) became seizure free. Fourteen patients (18%) experienced an increased seizure frequency (defined as >25% increase compared to the baseline period). Three of them developed status epilepticus (one with convulsive, and two with nonconvulsive status epilepticus), all within 4 weeks after introduction of levetiracetam. Four patients developed a greater tendency for generalisation of their partial seizures, i.e. they had more frequent secondary generalised tonic-clonic seizures.
Twenty-eight patients (36%) reported side effects; especially somnolence (14 patients, 18%) ( Table 3) . Irritability and aggression (three patients, 4%) were only seen in mentally retarded patients. Among the 50 patients without side effects 8 of them spontaneously reported that they felt better and more alert while taking levetiracetam. After 8 months, 43 patients were still treated with levetiracetam, i.e. a preliminary retention rate of 55%. Increased seizure frequency (14 patients, 18%) and lack of seizure-reducing effect (19 patients, 24%) were the most common causes for drug withdrawal.
All responders had localisation-related epilepsy. Otherwise, the responders did not differ from the nonresponders with respect to age, gender, duration of epilepsy, etiology of epilepsy, or seizure frequency. There was a slight tendency towards a weaker effect of the drug among those who were mentally retarded compared to those who were not. Antiepileptic effect was seen in all types of seizures, both partial and generalised.
There were no significant changes in the serum concentrations of the concomitant AEDs.
Children
At the end of the follow-up period, on average 8 months (3-14 months), 9 of the 44 children (20%) had >50% reduction in seizure frequency. Three of these patients (7%) became seizure free. In 19 patients (43%) levetiracetam was associated with an increased seizure frequency at a mean dose of 30 mg kg −1 (10-40 mg kg −1 ). The seizure aggravation appeared after an average treatment period of 7.7 weeks (3-12 weeks). Initially, half of these children had a good response (>50% reduction in seizure frequency), while the remaining children had no clinical benefit during titration. Three children developed a new seizure type, i.e. apnoeic attack (see Case 1). During titration one child developed impending complex partial status epilepticus and another patient developed nonconvulsive status epilepticus. Two children developed convulsive status epilepticus after 5 and 7 months on levetiracetam, respectively. None of them had previously experienced status epilepticus (see Case 2). Case 1. A 4-year-old boy with trisomi 10p and Lennox Gastaut Syndrome initially had a good response to levetiracetam with >50% decreased frequency of tonic seizures. After the dose had been titrated to 33 mg kg −1 , he suddenly developed apnoeic attacks every 30 minutes. He was admitted to hospital, and levitiracetam was withdrawn. Forty-eight hours later the apnoeic attacks disappeared, and his seizure frequency returned to baseline level.
Case 2.
A 10-year-old girl with cryptogenic partial epilepsy had a baseline seizure frequency of 15 seizures per day (tonic and tonic-clonic seizures). On a levetiracetam dose titrated from 10 to 30 mg kg −1 her seizure frequency was reduced to five to seven seizures per day, but on 40 mg kg −1 the seizure frequency increased to 20 seizures per day. The dose was reduced to 15 mg kg −1 and kept constant during the following 4 months. Her seizure frequency in this period was five to seven seizures per day. Then she suddenly developed tonic-clonic status epilepticus. Levetiracetam was withdrawn. She is now being treated with vagal nerve stimulation (VNS) and has been seizure free for more than 6 months. We have no other explanation to the development of status epilepticus in this patient other than a possible relationship to levetiracetam.
Effect of levetiracetam was seen both in partial and generalised seizures, generalised tonic-clonic seizures being the seizure type most often affected. The most frequently reported side effects were somnolence, dizziness, and ataxia. 'Forced normalisation' with psychosis was seen in one patient (Table 4) .
At the end of the follow-up period (mean 8 months) levetiracetam had been withdrawn in 29 patients (66%), mostly due to increased seizure frequency (19 patients, 43%) and lack of effect (10 patients, 23%). In all patients in whom levetiracetam was associated with an increased seizure frequency, withdrawal of the drug led to a marked seizure reduction. At the end of the follow-up period the retention rate of levetiracetam in the children was 34%. 
DISCUSSION
The seizure-reducing effect of levetiracetam as addon therapy achieved in the adult patients was fairly comparable to reports in previous studies 3 . In most patients the drug seemed to be well tolerated, and no clinically significant drug interactions were encountered. However, the relatively high proportion of patients with a paradoxical effect of levetiracetam (adults, 18%; children, 43%) has previously not been reported. The results from this study must be interpreted with caution. As the patients are recruited from a referral center, there is a selection bias against patients with very difficult-to-treat epilepsy. The lack of a control group is another limitation. On the other hand, we believe that the study conditions closely resemble everyday clinical practice. Hence, the results are probably representative for patients with intractable epilepsy.
In the last two decades there has been accumulating evidence that several AEDs (phenytoin, CBZ, vigabatrin, benzodiazepines, LTG, topiramate (TPM), tiagabine) may induce worsening of epilepsy by aggravating pre-existing seizures or/and triggering new seizure types 5, 6 . However, much of the evidence for this has been published in anecdotal form or is based on a small number of patients. Clinicians often face great difficulties in establishing a correct cause-effect relationship between the introduction of an AED and worsening of seizures. Ideally, it would be necessary to show improvement after withdrawal of the drug followed by renewed worsening secondary to its re-introduction. Such a procedure would, however, be unethical. The biological mechanisms involved in this phenomenon are unknown. Sometimes increased seizure frequency is triggered by an AED overdosage, most frequently reported for phenytoin 7 . Seizure aggravation has also been associated with different AEDs at nontoxic serum concentrations. It is mounting evidence that these AEDs may provoke aggravation purely by a pharmacodynamic mechanism; whether this is due to inappropriate choice of the AED, or to a paradoxical reaction is controversial 8 .
Seizure aggravation triggered by AEDs is probably more common in children than in adults, especially among mentally retarded children with 'mixed seizure disorders' 8 . AEDs with a defined mechanism of action, particularly GABA-ergic drugs, are likely to provoke generalised seizures. For example vigabatrin may trigger myoclonic jerks and absences, and benzodiazepines may trigger tonic seizures in patients with Lennox Gastaut Syndrome 9, 10 . Some possible explanations for seizure aggravation are listed in Table 5 .
We have no plausible explanation why an addition of levetiracetam apparently caused a seizure aggravation in several patients in the present study. There was Retrospectively, one may speculate if the dose escalation was too fast or the target dose too high, at least in some patients. Among the children we noticed that some patients treated with high doses of levetiracetam, >30 mg kg −1 , experienced a 'paradoxical intoxication' i.e. an increased seizure frequency without other signs of intoxication. The fact that the seizure frequency returned to baseline levels after levetiracetam had been withdrawn, argues against the assertion that the observed seizure exacerbation was part of natural fluctuations. Some of the children experienced increased seizure frequency after several months of good seizure control on a stable levetiracetam dosage. Withdrawal of the drug led to a marked seizure reduction. The explanation for this remains unknown.
The number of adult patients with generalised epilepsies was too small to evaluate the efficacy of levetiracetam in such epilepsies. Also the children group was too small and too heterogeneous to estimate the effect of levetiracetam in different epilepsy syndromes.
Based on our preliminary clinical experience levetiracetam seems to be a good alternative as an add-on treatment in patients with partial onset seizures, mostly due to good efficacy and no pharmacokinetic interactions. We propose a lower initial dose and a slower dose escalation than recommended by the manufacturer; in adults 250 mg daily as an initial dose, increasing the dose with 250 mg per week, and in children 5 mg kg −1 as an initial dose, especially in mentally retarded children, increasing the dose with 5 mg kg −1 every second week. However, due to the possible relationship between levetiracetam doses above 30 mg kg −1 and a paradoxical effect in children, doses above 20 mg kg −1 must be introduced with caution. If increased seizure frequency or apnoeic attacks occur, a gradual dose reduction or withdrawal of the drug is recommended.
In an ongoing study we are investigating a possible relationship between clinical efficacy/paradoxical effect and serum concentrations of levetiracetam, as well as the influence of a slow dose escalation.
